Pfiz­er spin­out Spring­Works gets FDA pri­or­i­ty re­view for lead drug

A Pfiz­er spin­out is get­ting a quick date with reg­u­la­tors for its “pipeline-in-a-prod­uct.”

Spring­Works Ther­a­peu­tics an­nounced Mon­day morn­ing that the FDA grant­ed nirogace­s­tat, the biotech’s lead can­di­date, pri­or­i­ty re­view for adults with desmoid tu­mors. Should the drug win ap­proval, it would be the com­pa­ny’s first since be­ing spun out of Pfiz­er five and a half years ago.

The FDA will make a de­ci­sion by Aug. 27, Spring­Works said in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.